The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Implementing genomic testing into myeloma centers: advice for fellows and trainees
Francesco Maura, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the key takeaways from his Meet the Expert session on genomics and epigenetics in multiple myeloma. Dr Maura notes that a common question from fellows and trainees is how to implement genomic analysis in their own institutions, and suggests that while whole-genome sequencing may not be feasible, targeted panels can be a more accessible and informative alternative to traditional methods like fluorescence in situ hybridization (FISH). This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Our session was mostly oriented towards fellows and trainees, so we went through some very easy concepts for experts, but something very important like quality of your data when you generate the data, how to understand if they’re good or bad, and how to interpret the data and how to move with consistency so every paper or study you do in different settings has the same methodology and ensuring that they are reproducible...
Our session was mostly oriented towards fellows and trainees, so we went through some very easy concepts for experts, but something very important like quality of your data when you generate the data, how to understand if they’re good or bad, and how to interpret the data and how to move with consistency so every paper or study you do in different settings has the same methodology and ensuring that they are reproducible. I think it’s often a very overlooked problem. Like people think that the purity is always high, our samples are always good, but most of the time the samples are actually bad, including in FISH, which is represented as the best that we have right now. But I think overall, that’s important to highlight the quality aspect of it. But the main question that you always have is, how can I do this in my place? And the answer is that most of the time you can’t, at least not whole genome sequencing. But you can definitely do a targeted panel. The problem is that institutions are not ready to commit to it for different reasons, because technically a targeted panel is cheaper than FISH. It’s more comprehensive, it’s more informative, but it’s not done routinely, but FISH is done routinely. So I think it’s just like we need a sort of conversion, but every conversion, like from fossil fuel to something better, it’s always hard, so it’s going to take time.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
